Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment
Abstract
:1. Introduction
2. Results
2.1. Study Design
2.2. Clinical Information
2.3. Peptidomic Analysis
2.4. Bioinformatic Analysis
3. Discussion
4. Materials and Methods
4.1. Study Population and Sample Collection
4.2. Sample Preparation and CE-MS Analysis
4.3. Statistical Analysis
4.4. Bioinformatic Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Cho, N.H.; Shaw, J.E.; Karuranga, S.; Huang, Y.; da Rocha Fernandes, J.D.; Ohlrogge, A.W.; Malanda, B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 2018, 138, 271–281. [Google Scholar] [CrossRef] [PubMed]
- Sun, H.; Saeedi, P.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B.B.; Stein, C.; Basit, A.; Chan, J.C.N.; Mbanya, J.C.; et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022, 183, 109119. [Google Scholar] [CrossRef] [PubMed]
- Kotwas, A.; Karakiewicz, B.; Zabielska, P.; Wieder-Huszla, S.; Jurczak, A. Epidemiological factors for type 2 diabetes mellitus: Evidence from the Global Burden of Disease. Arch. Public Health Arch. Belg. Sante Publique 2021, 79, 110. [Google Scholar] [CrossRef] [PubMed]
- Tinajero, M.G.; Malik, V.S. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinol. Metab. Clin. N. Am. 2021, 50, 337–355. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, A.M. Highlighting Diabetes Mellitus: The Epidemic Continues. Arterioscler. Thromb. Vasc. Biol. 2018, 38, e1–e8. [Google Scholar] [CrossRef] [PubMed]
- Beckman, J.A.; Creager, M.A. Vascular Complications of Diabetes. Circ. Res. 2016, 118, 1771–1785. [Google Scholar] [CrossRef] [PubMed]
- Thipsawat, S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature. Diabetes Vasc. Dis. Res. 2021, 18, 14791641211058856. [Google Scholar] [CrossRef] [PubMed]
- Nauck, M.A.; Wefers, J.; Meier, J.J. Treatment of type 2 diabetes: Challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021, 9, 525–544. [Google Scholar] [CrossRef]
- Artasensi, A.; Pedretti, A.; Vistoli, G.; Fumagalli, L. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules 2020, 25, 1987. [Google Scholar] [CrossRef]
- Sheahan, K.H.; Wahlberg, E.A.; Gilbert, M.P. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad. Med. J. 2020, 96, 156–161. [Google Scholar] [CrossRef]
- DeFronzo, R.A.; Triplitt, C.L.; Abdul-Ghani, M.; Cersosimo, E. Novel Agents for the Treatment of Type 2 Diabetes. Diabetes Spectr. A Publ. Am. Diabetes Assoc. 2014, 27, 100–112. [Google Scholar] [CrossRef]
- Abdul-Ghani, M.; DeFronzo, R.A. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Diabetes Care 2017, 40, 1121–1127. [Google Scholar] [CrossRef] [PubMed]
- Brunton, S.A.; Wysham, C.H. GLP-1 receptor agonists in the treatment of type 2 diabetes: Role and clinical experience to date. Postgrad. Med. 2020, 132, 3–14. [Google Scholar] [CrossRef] [PubMed]
- Defronzo, R.A. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58, 773–795. [Google Scholar] [CrossRef] [PubMed]
- Taylor, S.I.; Yazdi, Z.S.; Beitelshees, A.L. Pharmacological treatment of hyperglycemia in type 2 diabetes. J. Clin. Investig. 2021, 131, e142243. [Google Scholar] [CrossRef] [PubMed]
- Holst, J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87, 1409–1439. [Google Scholar] [CrossRef] [PubMed]
- Gentilella, R.; Pechtner, V.; Corcos, A.; Consoli, A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: Are they all the same? Diabetes/Metab. Res. Rev. 2019, 35, e3070. [Google Scholar] [CrossRef]
- Greco, E.V.; Russo, G.; Giandalia, A.; Viazzi, F.; Pontremoli, R.; De Cosmo, S. GLP-1 Receptor Agonists and Kidney Protection. Medicina 2019, 55, 233. [Google Scholar] [CrossRef]
- Nauck, M.A.; Quast, D.R.; Wefers, J.; Meier, J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes—State-of-the-art. Mol. Metab. 2021, 46, 101102. [Google Scholar] [CrossRef]
- Sirolli, V.; Pieroni, L.; Di Liberato, L.; Urbani, A.; Bonomini, M. Urinary Peptidomic Biomarkers in Kidney Diseases. Int. J. Mol. Sci. 2019, 21, 96. [Google Scholar] [CrossRef]
- Latosinska, A.; Siwy, J.; Faguer, S.; Beige, J.; Mischak, H.; Schanstra, J.P. Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease. Proteom. Clin. Appl. 2021, 15, e2000027. [Google Scholar] [CrossRef] [PubMed]
- Siwy, J.; Klein, T.; Rosler, M.; von Eynatten, M. Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial. Proteom. Clin. Appl. 2019, 13, e1800144. [Google Scholar] [CrossRef] [PubMed]
- Rossing, K.; Mischak, H.; Dakna, M.; Zurbig, P.; Novak, J.; Julian, B.A.; Good, D.M.; Coon, J.J.; Tarnow, L.; Rossing, P. Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol. 2008, 19, 1283–1290. [Google Scholar] [CrossRef] [PubMed]
- Schechter, M.; Leibowitz, G.; Mosenzon, O. Paving the way to precision medicine for diabetic kidney disease: The PRIORITY trial. Ann. Transl. Med. 2020, 8, 1698. [Google Scholar] [CrossRef] [PubMed]
- Andersen, S.; Mischak, H.; Zurbig, P.; Parving, H.H.; Rossing, P. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol. 2010, 11, 29. [Google Scholar] [CrossRef]
- He, T.; Pejchinovski, M.; Mullen, W.; Beige, J.; Mischak, H.; Jankowski, V. Peptides in Plasma, Urine, and Dialysate: Toward Unravelling Renal Peptide Handling. Proteom. Clin. Appl. 2021, 15, e2000029. [Google Scholar] [CrossRef] [PubMed]
- Mavrogeorgis, E.; Mischak, H.; Latosinska, A.; Vlahou, A.; Schanstra, J.P.; Siwy, J.; Jankowski, V.; Beige, J.; Jankowski, J. Collagen-Derived Peptides in CKD: A Link to Fibrosis. Toxins 2021, 14, 10. [Google Scholar] [CrossRef] [PubMed]
- Genovese, F.; Manresa, A.A.; Leeming, D.J.; Karsdal, M.A.; Boor, P. The extracellular matrix in the kidney: A source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenes. Tissue Repair 2014, 7, 4. [Google Scholar] [CrossRef]
- Ding, H.X.; Dong, N.X.; Zhou, C.X.; Wang, F.J.; Xing, N.; Ma, H.F.; Hou, L. Liraglutide Attenuates Restenosis After Vascular Injury in Rabbits With Diabetes Via the TGF-beta/Smad3 Signaling Pathway. Altern. Ther. Health Med. 2022, 28, 22–28. [Google Scholar]
- Cardoso, L.E.M.; Marinho, T.S.; Martins, F.F.; Aguila, M.B.; Mandarim-de-Lacerda, C.A. Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice. Life Sci. 2023, 319, 121502. [Google Scholar] [CrossRef]
- Gallego-Colon, E.; Klych-Ratuszny, A.; Kosowska, A.; Garczorz, W.; Aghdam, M.R.F.; Wozniak, M.; Francuz, T. Exenatide modulates metalloproteinase expression in human cardiac smooth muscle cells via the inhibition of Akt signaling pathway. Pharmacol. Rep. 2018, 70, 178–183. [Google Scholar] [CrossRef] [PubMed]
- Garczorz, W.; Gallego-Colon, E.; Kosowska, A.; Siemianowicz, K.; Klych-Ratuszny, A.; Wozniak, M.; Aghdam, M.R.F.; Francuz, T.; Dorecka, M. Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-alpha stimulated human retinal pigment epithelial cells. Pharmacol. Rep. 2019, 71, 175–182. [Google Scholar] [CrossRef] [PubMed]
- Dehghan, F.; Soori, R.; Gholami, K.; Abolmaesoomi, M.; Yusof, A.; Muniandy, S.; Heidarzadeh, S.; Farzanegi, P.; Ali Azarbayjani, M. Purslane (Portulaca oleracea) Seed Consumption And Aerobic Training Improves Biomarkers Associated with Atherosclerosis in Women with Type 2 Diabetes (T2D). Sci. Rep. 2016, 6, 37819. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Chen, J.; Li, B.; Fang, X. The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type II collagen and aggrecan in human SW1353 chondrocytes. Chem. Biol. Interact. 2020, 322, 108968. [Google Scholar] [CrossRef] [PubMed]
- Tao, Y.; Ge, G.; Wang, Q.; Wang, W.; Zhang, W.; Bai, J.; Lin, J.; Shen, J.; Guo, X.; Xu, Y.; et al. Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. IUBMB Life 2019, 71, 969–977. [Google Scholar] [CrossRef] [PubMed]
- Rafiullah, M.; Benabdelkamel, H.; Masood, A.; Ekhzaimy, A.A.; Musambil, M.; Joy, S.S.; Alfadda, A.A. Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment. Curr. Issues Mol. Biol. 2023, 45, 1407–1421. [Google Scholar] [CrossRef] [PubMed]
- Adiels, M.; Taskinen, M.R.; Bjornson, E.; Andersson, L.; Matikainen, N.; Soderlund, S.; Kahri, J.; Hakkarainen, A.; Lundbom, N.; Sihlbom, C.; et al. Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia. Diabetes Obes. Metab. 2019, 21, 1861–1870. [Google Scholar] [CrossRef]
- Choi, Y.W.; Kim, Y.G.; Song, M.Y.; Moon, J.Y.; Jeong, K.H.; Lee, T.W.; Ihm, C.G.; Park, K.S.; Lee, S.H. Potential urine proteomics biomarkers for primary nephrotic syndrome. Clin. Proteom. 2017, 14, 18. [Google Scholar] [CrossRef]
- Wang, H.; Huang, X.; Xu, P.; Liu, X.; Zhou, Z.; Wang, F.; Li, J.; Wang, Y.; Xian, X.; Liu, G.; et al. Apolipoprotein C3 aggravates diabetic nephropathy in type 1 diabetes by activating the renal TLR2/NF-κB pathway. Metabolism 2021, 119, 154740. [Google Scholar] [CrossRef]
- Marques, E.S.; Formato, E.; Liang, W.; Leonard, E.; Timme-Laragy, A.R. Relationships between type 2 diabetes, cell dysfunction, and redox signaling: A meta-analysis of single-cell gene expression of human pancreatic alpha- and beta-cells. J. Diabetes 2022, 14, 34–51. [Google Scholar] [CrossRef]
- Pasello, M.; Manara, M.C.; Scotlandi, K. CD99 at the crossroads of physiology and pathology. J. Cell Commun. Signal. 2018, 12, 55–68. [Google Scholar] [CrossRef] [PubMed]
- Lou, O.; Alcaide, P.; Luscinskas, F.W.; Muller, W.A. CD99 is a key mediator of the transendothelial migration of neutrophils. J. Immunol. 2007, 178, 1136–1143. [Google Scholar] [CrossRef] [PubMed]
- Yang, K.; Sun, J.; Zhang, Z.; Xiao, M.; Ren, D.; Liu, S.M. Reduction of mRNA m(6)A associates with glucose metabolism via YTHDC1 in human and mice. Diabetes Res. Clin. Pract. 2023, 198, 110607. [Google Scholar] [CrossRef] [PubMed]
- Gluvic, Z.; Obradovic, M.; Lackovic, M.; Samardzic, V.; Tica Jevtic, J.; Essack, M.; Bajic, V.B.; Isenovic, E.R. HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review. J. Clin. Pharm. Ther. 2020, 45, 379–383. [Google Scholar] [CrossRef]
- Pandey, G.K.; Balasubramanyam, J.; Balakumar, M.; Deepa, M.; Anjana, R.M.; Abhijit, S.; Kaviya, A.; Velmurugan, K.; Miranda, P.; Balasubramanyam, M.; et al. Altered Circulating Levels of Retinol Binding Protein 4 and Transthyretin in Relation to Insulin Resistance, Obesity, and Glucose Intolerance in Asian Indians. Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol. 2015, 21, 861–869. [Google Scholar] [CrossRef] [PubMed]
- Hu, X.; Guo, Q.; Wang, X.; Wang, Q.; Chen, L.; Sun, T.; Li, P.; Shan, Z.; Liu, L.; Gao, C.; et al. Plasma Transthyretin Levels and Risk of Type 2 Diabetes Mellitus and Impaired Glucose Regulation in a Chinese Population. Nutrients 2022, 14, 2953. [Google Scholar] [CrossRef] [PubMed]
- Henze, A.; Frey, S.K.; Raila, J.; Scholze, A.; Spranger, J.; Weickert, M.O.; Tepel, M.; Zidek, W.; Schweigert, F.J. Alterations of retinol-binding protein 4 species in patients with different stages of chronic kidney disease and their relation to lipid parameters. Biochem. Biophys. Res. Commun. 2010, 393, 79–83. [Google Scholar] [CrossRef] [PubMed]
- Fernandez-Real, J.M.; Grasa, M.; Casamitjana, R.; Pugeat, M.; Barret, C.; Ricart, W. Plasma total and glycosylated corticosteroid-binding globulin levels are associated with insulin secretion. J. Clin. Endocrinol. Metab. 1999, 84, 3192–3196. [Google Scholar] [CrossRef]
- Fernandez-Real, J.M.; Pugeat, M.; Grasa, M.; Broch, M.; Vendrell, J.; Brun, J.; Ricart, W. Serum corticosteroid-binding globulin concentration and insulin resistance syndrome: A population study. J. Clin. Endocrinol. Metab. 2002, 87, 4686–4690. [Google Scholar] [CrossRef]
- Benchoula, K.; Parhar, I.S.; Hwa, W.E. The molecular mechanism of vgf in appetite, lipids, and insulin regulation. Pharmacol. Res. 2021, 172, 105855. [Google Scholar] [CrossRef]
- Derezanin, L.; Blazyte, A.; Dobrynin, P.; Duchene, D.A.; Grau, J.H.; Jeon, S.; Kliver, S.; Koepfli, K.P.; Meneghini, D.; Preick, M.; et al. Multiple types of genomic variation contribute to adaptive traits in the mustelid subfamily Guloninae. Mol. Ecol. 2022, 31, 2898–2919. [Google Scholar] [CrossRef] [PubMed]
- Sundkvist, A.; Myte, R.; Boden, S.; Enroth, S.; Gyllensten, U.; Harlid, S.; van Guelpen, B. Targeted plasma proteomics identifies a novel, robust association between cornulin and Swedish moist snuff. Sci. Rep. 2018, 8, 2320. [Google Scholar] [CrossRef] [PubMed]
- Odum, E.P.; Young, E.E. Elevated cardiac troponin I, creatine kinase and myoglobin and their relationship with cardiovascular risk factors in patients with type 2 diabetes. Diabetes Metab. Syndr. 2018, 12, 141–145. [Google Scholar] [CrossRef] [PubMed]
- Wu, R.; Shu, Z.; Zou, F.; Zhao, S.; Chan, S.; Hu, Y.; Xiang, H.; Chen, S.; Fu, L.; Cao, D.; et al. Identifying myoglobin as a mediator of diabetic kidney disease: A machine learning-based cross-sectional study. Sci. Rep. 2022, 12, 21411. [Google Scholar] [CrossRef]
- Krawczyk, K.M.; Nilsson, H.; Nystrom, J.; Lindgren, D.; Leandersson, K.; Sward, K.; Johansson, M.E. Localization and Regulation of Polymeric Ig Receptor in Healthy and Diseased Human Kidney. Am. J. Pathol. 2019, 189, 1933–1944. [Google Scholar] [CrossRef] [PubMed]
- He, T.; Mischak, M.; Clark, A.L.; Campbell, R.T.; Delles, C.; Diez, J.; Filippatos, G.; Mebazaa, A.; McMurray, J.J.V.; Gonzalez, A.; et al. Urinary peptides in heart failure: A link to molecular pathophysiology. Eur. J. Heart Fail. 2021, 23, 1875–1887. [Google Scholar] [CrossRef] [PubMed]
- Eder, S.; Leierer, J.; Kerschbaum, J.; Rosivall, L.; Wiecek, A.; de Zeeuw, D.; Mark, P.B.; Heinze, G.; Rossing, P.; Heerspink, H.L.; et al. A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID)—Study Design and Baseline Characteristics. Kidney Blood Press. Res. 2018, 43, 181–190. [Google Scholar] [CrossRef]
- Latosinska, A.; Siwy, J.; Cherney, D.Z.; Perkins, B.A.; Mischak, H.; Beige, J. SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: An in-silico proof-of-principle of proteomics-based drug repurposing. Proteomics 2021, 21, e2100160. [Google Scholar] [CrossRef]
- Zurbig, P.; Renfrow, M.B.; Schiffer, E.; Novak, J.; Walden, M.; Wittke, S.; Just, I.; Pelzing, M.; Neususs, C.; Theodorescu, D.; et al. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006, 27, 2111–2125. [Google Scholar] [CrossRef]
- Schanstra, J.P.; Zurbig, P.; Alkhalaf, A.; Argiles, A.; Bakker, S.J.; Beige, J.; Bilo, H.J.; Chatzikyrkou, C.; Dakna, M.; Dawson, J.; et al. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. J. Am. Soc. Nephrol. 2015, 26, 1999–2010. [Google Scholar] [CrossRef]
- Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate—A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B 1995, 57, 289–300. [Google Scholar] [CrossRef]
- Franceschini, A.; Szklarczyk, D.; Frankild, S.; Kuhn, M.; Simonovic, M.; Roth, A.; Lin, J.; Minguez, P.; Bork, P.; von Mering, C.; et al. STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013, 41, D808–D815. [Google Scholar] [CrossRef] [PubMed]
- von Mering, C.; Jensen, L.J.; Snel, B.; Hooper, S.D.; Krupp, M.; Foglierini, M.; Jouffre, N.; Huynen, M.A.; Bork, P. STRING: Known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res. 2005, 33, D433–D437. [Google Scholar] [CrossRef] [PubMed]
Clinical Information a | T2DM Patients (n = 32) | p-Value b | |
---|---|---|---|
Pre-Treatment | Post-Treatment | ||
Age (years) | 63.7 ± 7.3 | ||
Sex (% Females) | 56.3 | ||
HbA1C (%) | 8.0 ± 1.4 | 8.0 ± 1.5 | 0.731 |
BW (kg) | 98.3 ± 16.1 | 98.8 ± 20.3 | 0.771 |
BMI (kg/m2) | 33.2 ± 6.3 | 33.2 ± 6.9 | 0.915 |
SBP (mmHg) | 139.2 ± 14.4 | 137.1 ± 12.6 | 0.385 |
DBP (mmHg) | 81.1 ± 7.7 | 81.3 ± 8.2 | 0.906 |
eGFR (mL/min/1.73 m2) | 67.7 ± 14.5 | 67.6 ± 15.6 | 0.965 |
UACR (mg/g) | 33.6 ± 58.6 | 25.5 ± 44.8 | 0.248 |
UCREA (mg/dL) | 103.9 ± 41.6 | 96.6 ± 50.7 | 0.429 |
UniProt ID | Gene Symbol | Protein Name | Number of Peptides | |
---|---|---|---|---|
Total | Regulation after Treatment | |||
P02461 | COL3A1 | Collagen alpha-1(III) chain | 16 | ↓ (13) + ↑ (3) |
P02452 | COL1A1 | Collagen alpha-1(I) chain | 15 | ↓ |
P08123 | COL1A2 | Collagen alpha-2(I) chain | 10 | ↓ (9) + ↑ (1) |
P02458 | COL2A1 | Collagen alpha-1(II) chain | 3 | ↓ |
P02462 | COL4A1 | Collagen alpha-1(IV) chain | 2 | ↓ |
P05997 | COL5A2 | Collagen alpha-2(V) chain | 2 | ↓ |
P12107 | COL11A1 | Collagen alpha-1(XI) chain | 2 | ↓ |
P27658 | COL8A1 | Collagen alpha-1(VIII) chain | 1 | ↓ |
Q5TAT6 | COL13A1 | Collagen alpha-1(XIII) chain | 1 | ↓ |
Q05707 | COL14A1 | Collagen alpha-1(XIV) chain | 1 | ↓ |
Q07092 | COL16A1 | Collagen alpha-1(XVI) chain | 1 | ↓ |
P39060 | COL18A1 | Collagen alpha-1(XVIII) chain | 1 | ↓ |
P25067 | COL8A2 | Collagen alpha-2(VIII) chain | 1 | ↓ |
P29400 | COL4A5 | Collagen alpha-5(IV) chain | 1 | ↓ |
Q14031 | COL4A6 | Collagen alpha-6(IV) chain | 1 | ↓ |
P01009 | SERPINA1 | Alpha-1-antitrypsin | 1 | ↓ |
P02656 | APOC3 | Apolipoprotein C-III | 1 | ↓ |
P14209 | CD99 | CD99 antigen | 1 | ↓ |
Q16630 | CPSF6 | Cleavage and polyadenylation specificity factor subunit 6 | 1 | ↓ |
Q9UBG3 | CRNN | Cornulin | 1 | ↓ |
P08185 | SERPINA6 | Corticosteroid-binding globulin | 1 | ↓ |
P69905 | HBA1; HBA2 | Hemoglobin subunit alpha | 1 | ↓ |
P02144 | MB | Myoglobin | 1 | ↓ |
O15240 | VGF | Neurosecretory protein VGF | 1 | ↓ |
P01833 | PIGR | Polymeric immunoglobulin receptor | 1 | ↓ |
P02766 | TTR | Transthyretin | 1 | ↓ |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lohia, S.; Siwy, J.; Mavrogeorgis, E.; Eder, S.; Thöni, S.; Mayer, G.; Mischak, H.; Vlahou, A.; Jankowski, V. Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment. Int. J. Mol. Sci. 2023, 24, 13540. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms241713540
Lohia S, Siwy J, Mavrogeorgis E, Eder S, Thöni S, Mayer G, Mischak H, Vlahou A, Jankowski V. Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment. International Journal of Molecular Sciences. 2023; 24(17):13540. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms241713540
Chicago/Turabian StyleLohia, Sonnal, Justyna Siwy, Emmanouil Mavrogeorgis, Susanne Eder, Stefanie Thöni, Gert Mayer, Harald Mischak, Antonia Vlahou, and Vera Jankowski. 2023. "Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment" International Journal of Molecular Sciences 24, no. 17: 13540. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms241713540